NL-OMON39672
Recruiting
Not Applicable
Mindfulness Based Cognitive Therapy (MBCT) for treatment refractory anxiety disorders - MBCT for anxiety disorders
PsyQ0 sites128 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- PsyQ
- Enrollment
- 128
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- still fullfilling the criteria for an DSM IV axis 1 anxiety disorder
- •\- refrain from treatment and counseling more frequently than once a month during the intervention
- •\- stable use of anti\-depressant medication or Benzodiazepines at leatst 3 months before inclusion
- •\- Willingness to keep the dosage on a constant level during the intervention
- •\-willingness to complete daily homework assignments between sessions during the MBCT course.
Exclusion Criteria
- •Primary axis 1 diagnosis of substance abuse or dependence, suicidality or psychotic symptoms
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
ADO CTCL-3 (Tarado): Multicentric therapy protocol for bexarotene (Targretin ®) monotherapy in pretreated CTCL stage =Ib with clear assignment to a EORTC-DiagnosisTCELLLYMPHOMAC84Mature T/NK-cell lymphomasDRKS00003693niversitätsklinikum Schleswig-Holstein Campus Kiel200
Active, not recruiting
Not Applicable
A phase 3, double-blind, placebo-controlled, multicentre, randomised-withdrawal, long-term maintenance of efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 with Attention-deficit/Hyperactivity DisorderADHDMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2009-018161-12-ITShire Development Inc.510
Recruiting
Phase 1
Asciminib treatment optimization in = 3rd line CML-CPChronic Myelogenous Leukemia in chronic phase (CML-CP)MedDRA version: 21.0Level: LLTClassification code: 10009012Term: Chronic myelogenous leukemia Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511381-36-00ovartis Pharma AG205
Active, not recruiting
Phase 1
Study to assess the long term safety and efficacy of Guanfacine-Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 14.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-018161-12-GBShire Development Inc510
Active, not recruiting
Not Applicable
Study to assess the long term safety and efficacy of Guanfacine- Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 15.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2009-018161-12-NLShire Development Inc510